Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 2

recruiting
3 975
countries
28
conditions
2 106

21 trials match your criteria

B precursor type acute leukaemia

Not yet recruiting

Study of asciminib, dexamethasone, blinatumomab, and vincristine sulfate in children and young adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab

Acute lymphocytic leukaemia+1

Not yet recruiting

A study to evaluate the safety and effectiveness of subcutaneous blinatumomab in adults and adolescents with relapsed, refractory, or minimal residual disease positive B-cell precursor acute lymphoblastic leukemia.

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Blinatumomab

Testing inotuzumab ozogamicin and blinatumomab with drug combination for children with relapsed precursor B-cell acute lymphoblastic leukemia

Not yet recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab

Acute lymphocytic leukaemia+2

Not yet recruiting

A Study of Blinatumomab in Children with Relapsed or Treatment-Resistant B Cell Acute Lymphoblastic Leukemia with Remaining Disease Traces

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Blinatumomab

Philadelphia positive acute lymphocytic leukaemia

Not recruiting

Study on Ponatinib and Blinatumomab for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab

Acute lymphocytic leukaemia

Not recruiting

Study of Venetoclax and Blinatumomab for Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab

B precursor type acute leukaemia

Not recruiting

Study on Adding Blinatumomab to Treatment for Adults with Precursor B-Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab

Acute lymphocytic leukaemia

Not recruiting

Study on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Blinatumomab

Acute lymphocytic leukaemia

Not recruiting

Study on Acute Lymphoblastic Leukemia Treatment in Children and Adolescents Using Bortezomib, Blinatumomab, and Methotrexate Combination

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Blinatumomab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.